Newborn variants may flag childhood cancer predisposition
Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.
-
By
-
Andrea Surnit
-
August 28, 2026
-
Clinical Scorecard: Newborn variants may flag childhood cancer predisposition
At a Glance
| Category | Detail |
|---|
| Condition | Childhood cancer predisposition |
| Key Mechanisms | Pathogenic or likely pathogenic germline variants detected in newborns |
| Target Population | Newborns in Michigan from 1987 to 2020 |
| Care Setting | Genomic newborn screening |
Key Highlights
- 7% of pediatric patients developed malignancies associated with germline variants detectable at birth.
- RB1 variants were most common, accounting for 69 of the detected variants.
- Patients with detected variants received cancer diagnoses at a median age of 14 months.
- 130 patients developed tumors with a well-established association with the affected gene.
- 9% of variant carriers developed a second cancer compared to 5% of noncarriers.
Guideline-Based Recommendations
Diagnosis
- Targeted genomic sequencing of newborn dried blood spots.
Management
- Consider gene-specific surveillance guidelines for early detection.
Monitoring & Follow-up
- Monitor for early-onset cancers in newborns with detected variants.
Risks
- Potential for underestimating the number of genetically at-risk newborns.
Patient & Prescribing Data
Newborns with detected cancer-predisposition variants
No significant differences in treatment or overall survival based on variant status.
Clinical Best Practices
- Implement genomic newborn screening for selected cancer-risk genes.
- Conduct prospective research to evaluate clinical outcomes of newborn screening.
Related Resources & Content
